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Executive Summary
Cost and Cost Effectiveness of Treatment as Usual in 
Drug Misuse Services
AIMS & OBJECTIVES
The aim of the study was to gather information about what 
actually happens in a sample of UK Drug Treatment Services 
in terms of what kind of interventions are delivered and how 
effective and cost effective are these interventions when 
judged against key outcome domains.  
The specific objectives were:
In estimating cost effectiveness it was assumed that treatment 
was the major determinant of improved outcome. It can be 
argued that such an assertion would require comparison with 
a no treatment control group. However, given the weight of 
evidence that ‘treatment works’, it would have been unethical 
to have a no treatment control. Moreover, treatment as usual 
is often used as the control in trials of novel treatments.
BACKGROUND
The UK Drug Strategy 1998/2008 has attempted to bring as 
many drug users as possible into treatment. Many individuals 
now in treatment have come through the Criminal Justice 
System.  One can reasonably assume from this that, on the 
one hand, there are significant numbers in treatment who 
are not looking to change their drug using behaviour but, 
on the other hand, retaining these people in treatment is 
likely to deliver significant Criminal Justice System savings. 
The effect of the Strategy has been that more people enter 
the treatment system and more people stay on substitute 
prescriptions. In order to contain the demand, commissioners 
are moving away from open ended treatment packages 
to time limited packages. This study sets out how service 
providers define their own care packages and how effective 
these are in engaging and retaining service users.  
Few UK studies have attempted to estimate the cost of substance 
misuse services. Where structured psychosocial treatments 
have been compared, trials have found few differences 
between the specific treatments under investigation. In the 
UK Alcohol Treatment Trial the average cost of Motivational 
Enhancement Therapy was £129.00 as compared to the 
more intensive Social Behavioural and Network Therapy 
costing £221.00. However, both delivered similar cost 
effectiveness and both fell within the NICE benchmark of 
£20,000 - £30,000 to deliver one quality adjusted life year 
(QALY). In the National Treatment Outcome Research Study 
(NTORS) methadone maintenance programmes were found 
to cost between £7.00 and £98.00 per week. 
Cost and Cost Effectiveness studies need to be interpreted 
with great caution.  At first sight, there appears to be a huge 
diversity in both costs and outcomes. However, on closer 
inspection, it can be seen that costs have been estimated 
in different ways. Contributory variables are differences 
in accounting methods, differences in service user 
characteristics, and differences in the aims of treatment.
EXECUTIVE SUMMARY
POLICY RELEVANCE
Little is known about what actually happens when service 
users are referred to service provider agencies and engage in 
treatment.  Most research into treatment outcomes compares 
gold standard interventions against a novel treatment.  This 
is a legitimate way to test the optimal delivery of particular 
interventions but says little about the diversity of activity that 
is found in agencies across the UK.
The National Drug Strategy 1998/2008 has been 
supported by a substantial investment of government funds 
in drug misuse treatment agencies. This study contributes 
to an understanding of how the investment translates into 
treatment activity, and how the investment impacts on health 
and social care and the criminal justice system. This study 
contributes to the development of policy by:
 To describe treatment as usual in a range of   
 different drug misuse service providers.
 
 To estimate the range of costs of treatment as   
 usual.
 To estimate the cost effectiveness of treatment and
 investigate factors that facilitate and hinder   
 successful involvement.
 To measure the effectiveness of treatment as usual.
 Describing treatment as usual in a sample of UK
 drugs agencies 
 Estimating the cost of treatment in a sample of UK  
 drugs agencies 
 Prospectively estimating cost effectiveness
 Describing a methodology for routinely costing  
 treatment
 Further development of treatment process and   
 outcome measures
 Informing the further refinement of Models of Care
FINDINGS
All of the service providers were found to have made 
a positive response to help seekers and all delivered 
statistically significant health and social gains. Broadly 
speaking, treatment took people out of the criminal justice 
system, with highly significant public sector cost savings, 
and got people into health and social care systems, with 
some additional public sector cost.  The size of the treatment 
effect was similar to that found in other areas of healthcare 
and within the NICE approved cost limit.  The key findings 
were:
1. The seven participating service providers were different 
in terms of:
 
2. Just over 40% of all people referred to the treatment 
providers never attended (during the recruitment period). 
Agencies tended to under-estimate their non attendance 
rates.
3. The outcome measures package, RESULT, worked 
well. Study participants were in less good general and 
psychological health than the general population: 0.74 
against 0.93 on the EQ-5D (general wellbeing) and 25.8 
against 56.3 on CORE-OM (psychological problems). 
4. At 6 month follow up there were statistically significant 
(p < 0.001) reductions in substance dependence, physical 
health symptoms, psychological health symptoms and an 
increase in social satisfaction.
5. Societal costs were reduced from a mean of £5,414 to 
£4,133.  The mean change of £1,281 at 6 months was 
the result of reduced criminal justice costs (-£1,813) and 
increased uptake on health and social care (+£532).
6. The mean cost of treatment for the 6 month period was 
£647 derived from a mean of 33 appointments. The range 
was £261 - £1,167 and 27 - 67 appointments (these 
include direct and indirect service delivery costs).
7. The range of interventions that agencies said they 
provided and the cost of these varied markedly. There was 
a high proportion of unstructured and prescribing related 
interventions as compared to manual based psychosocial 
interventions.
8. The mean change in Quality Adjusted Life Years (QALYs) 
for this study was 0.29 QALY in 6 months (NICE considers 
£20,000 - £30,000 an acceptable cost per 1.0 QALY 
gain).
9. At follow-up participants completed a Treatment 
Perceptions Questionnaire.  The mean score for perceptions 
about the staff was 2.78 and perceptions of the treatment 
programme was 2.73 (0 is the worst possible score and 4 
the best possible). A third of service users added comments 
about their treatment and these were overwhelmingly 
positive.
10. At some level all agencies expressed benefits from 
participating in this service orientated research. There is 
scope for improving service delivery by providing training 
in the delivery of interventions, by routine monitoring of 
process and outcomes, provision of routine supervision of 
practice and review of service costs.
METHODOLOGY
The study planned to recruit 400 service users from seven 
drug misuse agencies. The cohort was followed up at 6 
months and outcomes determined the costs of treatment 
and change in the key domains of substance use, substance 
dependence, social satisfaction, and psychological 
morbidity. The EuroQol was used as an outcome measure 
in order to allow comparisons with NICE criteria for cost 
effectiveness.
The seven participating agencies were intentionally chosen 
because of their differences. All of the agencies were 
community based but were drawn from different treatment 
sectors and were located in very different catchment areas. 
The intention was that participating agencies should form a 
reasonable cross section of UK service providers.
The follow-up procedure was developed from a methodology 
used in previous projects. The costing method was also 
developed from a methodology used in previous projects. 
The costings method took account of health, social, and 
criminal justice costs (NICE excludes criminal justice costs). 
 The size and ethnic mix of their catchment areas
 The service user characteristics 
 The size of the staff group and staff skills mix
 The role of the agency within the local treatment  
 system
 The treatments offered
 The range of parent organisations
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DISCUSSIONS AND RECOMMENDATIONS
The most striking finding from this study is the diversity of 
activity in different agencies which is somewhat surprising 
given the centralisation of control that has accompanied the 
National Drugs Strategy 1998/2008. In many ways the 
service users are also a diverse group, however, what is 
also striking is the extent to which service users have high 
levels of physical and psychological morbidity. This may not 
be surprising given the level of substance misuse including 
a very high prevalence of smokers but the implication is 
that engagement in treatment will, at least in the short term, 
result in increased use of health resources.  
It is recommended that:
It is not possible to know how representative of UK treatment 
providers the participating agencies might be. The agencies 
will readily be recognised as the kind of service providers 
commonly found in most towns and cities and offering 
commonly used interventions. It is likely, therefore, that 
findings from the study are generalisable.  
It would have been desirable to have a 3 month and 12 
month follow-up. Without the 12 month follow-up it is 
difficult to know how many people coming into treatment 
will successfully exit and how many will reinstate substance 
misuse behaviours and criminal activity. It cannot be 
assumed that good outcomes will be sustained particularly 
where substitute prescribing has been instrumental in 
bringing about early improvement.
The study has shown that it is possible to undertake good 
quality research in drug misuse services. All participating 
agencies expressed a belief that there had been benefits 
from the collaboration. Agencies cited improved data 
collection, a better understanding of outcome measures and 
improved retention of service users (by virtue of the follow-
ups) among the most important benefits of participating in 
this study.
 Agencies develop and adopt local outcome 
 measures. The RESULT outcomes package was
 found to be acceptable to both service users and  
 agencies.
 Agencies could rationalise the number and   
 variety of interventions offered.  Interventions 
 should be guideline based and staff should 
 demonstrate competence at delivering   
 interventions.
 Agencies should pay attention to treatment
 delivery as much as to the specific treatments   
 offered. Improved outcomes can be achieved   
 at relatively low cost by organisational support for 
 training and supervision of practice.
